WHD References

Home - WHD References

References

Bibliography

  1. Khomiak A, Brunner M, Kordes M, et al. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers. 2020;12(11):3234. doi:https://doi.org/10.3390/cancers12113234
  2. Lawler M, Davies L, Oberst S, et al. European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission. The Lancet Oncology. Published online November 2022. doi:https://doi.org/10.1016/s1470-2045(22)00540-x
  3. Mancera-Arteu M, Giménez E, Balmaña M, et al. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma. Journal of Proteomics. 2019;195:76-87. doi:https://doi.org/10.1016/j.jprot.2019.01.006
  4. Virág D, Kremmer T, Lőrincz K, et al. Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma. Molecules. 2021;26(19):6003. doi:https://doi.org/10.3390/molecules26196003
  5. World Health Organization. Cancer. World Health Organization. Published February 3, 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
  6. Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer. 2021;20(1). doi:https://doi.org/10.1186/s12943-021-01441-4
  7. Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Annals of Oncology. Published online April 2021. doi:https://doi.org/10.1016/j.annonc.2021.03.206
  8. Voutsadakis IA. The Landscape of PIK3CA Mutations in Colorectal Cancer. Clinical Colorectal Cancer. Published online February 2021. doi:https://doi.org/10.1016/j.clcc.2021.02.003
  9. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. International Journal of Cancer. 2021;149(4). doi:https://doi.org/10.1002/ijc.33588
  10. Duggan B, O’Rourke D, Anderson N, et al. Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific. Frontiers in Oncology. 2022;12:1009014. doi:https://doi.org/10.3389/fonc.2022.1009014


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular